The molecular basis for selective inhibition of unconventional mRNA splicing by an IRE1-binding small molecule

Benedict C. S. Cross(University of Cambridge), Heather P. Harding(University of Cambridge), Ian R. Baxendale(Durham University), Babal K. Jha(Cleveland Clinic), Robert H. Silverman(Cleveland Clinic Lerner College of Medicine), Thomas A. Neubert(New York University), David Ron(Institute for Medical Research), Paweł Sadowski(Queensland University of Technology), Peter J. Bond(Unilever (United Kingdom)), Jonathan M. Goodman(University of Cambridge), Jaroslav Žák(Scripps Research Institute)
Proceedings of the National Academy of Sciences
February 6, 2012
10.1073/pnas.1115623109
Cited by 594

Related Papers

Somatic <i>CALR</i> Mutations in Myeloproliferative Neoplasms with Nonmutated <i>JAK2</i>
|New England Journal of Medicine|2013|1.7k
ALS/FTD Mutation-Induced Phase Transition of FUS Liquid Droplets and Reversible Hydrogels into Irreversible Hydrogels Impairs RNP Granule Function
|Neuron|2015|917
An overview of the synthetic routes to the best selling drugs containing 6-membered heterocycles
|Beilstein Journal of Organic Chemistry|2013|841
Predicting the mutations generated by repair of Cas9-induced double-strand breaks
|Nature Biotechnology|2018|529
Increased sensitivity to dextran sodium sulfate colitis in IRE1β-deficient mice
|Journal of Clinical Investigation|2001|401